<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET>
<STUDY accession="ERP016813" alias="ena-STUDY-BGI-11-08-2016-05:39:28:008-442" center_name="Beijing Genome Institute">
     <IDENTIFIERS>
          <PRIMARY_ID>ERP016813</PRIMARY_ID>
          <SECONDARY_ID>PRJEB15111</SECONDARY_ID>
          <SUBMITTER_ID namespace="Beijing Genome Institute">ena-STUDY-BGI-11-08-2016-05:39:28:008-442</SUBMITTER_ID>
     </IDENTIFIERS>
     <DESCRIPTOR>
          <STUDY_TITLE>Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease</STUDY_TITLE>
          <STUDY_ABSTRACT>Coronary heart disease (CHD) is top risk factor for health in modern society, causing high mortality rate each year. However, there is no reliable way for early diagnosis and prevention of CHD so far. So study the mechanism of CHD and development of novel biomarkers is urgently needed. In this study, metabolomics and metagenomics technology are applied to discover new biomarkers from plasma and urine of 59 CHD patients and 43 healthy controls and trace their origin. We identify GlcNAc-6-P which has good diagnostic capability and can be used as potential biomarkers for CHD, together with mannitol and 15 plasma cholines. These identified metabolites show significant correlations with clinical biochemical indexes. Meanwhile, GlcNAc-6-P and mannitol are potential metabolites originated from intestinal microbiota. Association analysis on species and function levels between intestinal microbes and metabolites suggest a close correlation between Clostridium sp. HGF2 and GlcNAc-6-P, Clostridium sp. HGF2, Streptococcus sp. M143, Streptococcus sp. M334 and mannitol. These suggest the metabolic abnormality is significant and gut microbiota dysbiosis happens in CHD patients.</STUDY_ABSTRACT>
          <STUDY_DESCRIPTION>Coronary heart disease (CHD) is top risk factor for health in modern society, causing high mortality rate each year. However, there is no reliable way for early diagnosis and prevention of CHD so far. So study the mechanism of CHD and development of novel biomarkers is urgently needed. In this study, metabolomics and metagenomics technology are applied to discover new biomarkers from plasma and urine of 59 CHD patients and 43 healthy controls and trace their origin. We identify GlcNAc-6-P which has good diagnostic capability and can be used as potential biomarkers for CHD, together with mannitol and 15 plasma cholines. These identified metabolites show significant correlations with clinical biochemical indexes. Meanwhile, GlcNAc-6-P and mannitol are potential metabolites originated from intestinal microbiota. Association analysis on species and function levels between intestinal microbes and metabolites suggest a close correlation between Clostridium sp. HGF2 and GlcNAc-6-P, Clostridium sp. HGF2, Streptococcus sp. M143, Streptococcus sp. M334 and mannitol. These suggest the metabolic abnormality is significant and gut microbiota dysbiosis happens in CHD patients.</STUDY_DESCRIPTION>
          <CENTER_PROJECT_NAME>CHD102-metagenomics</CENTER_PROJECT_NAME>
          <STUDY_TYPE existing_study_type="Other"/>
     </DESCRIPTOR>
     <STUDY_LINKS>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>PUBMED</DB>
                    <ID>26932197</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SAMPLE</DB>
                    <ID>ERS1289677-ERS1289778</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-EXPERIMENT</DB>
                    <ID>ERX1649375-ERX1649476</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-RUN</DB>
                    <ID>ERR1578619-ERR1578720</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMISSION</DB>
                    <ID>ERA688177</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-FASTQ-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP016813&result=read_run&fields=run_accession,fastq_ftp,fastq_md5,fastq_bytes]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMITTED-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP016813&result=read_run&fields=run_accession,submitted_ftp,submitted_md5,submitted_bytes,submitted_format]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
     </STUDY_LINKS>
     <STUDY_ATTRIBUTES>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-SPOT-COUNT</TAG>
               <VALUE>2953032803</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-BASE-COUNT</TAG>
               <VALUE>590606560600</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-FIRST-PUBLIC</TAG>
               <VALUE>2016-10-10</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-LAST-UPDATE</TAG>
               <VALUE>2016-08-11</VALUE>
          </STUDY_ATTRIBUTE>
     </STUDY_ATTRIBUTES>
</STUDY>
</STUDY_SET>
